ASGPR Inhibitors
1 drugsAbout ASGPR
ASGPR is a C-type lectin receptor primarily on hepatocytes, mediating clearance of galactose-terminated glycoproteins. Its function in glycoprotein homeostasis and liver-specific expression make it a target for liver-directed drug delivery.
ASGPR's unique expression profile has spurred interest as a therapeutic target, particularly for liver-targeted therapies. Currently, there is no genetic evidence directly linking ASGPR to specific diseases.
RIVFLOZA is the only FDA-approved drug targeting ASGPR. It is an siRNA therapy developed by Novo Nordisk for one indication in the 'other' therapeutic area.
Top ASGPR Drugs
Novo Nordisk is the only company with an approved drug targeting ASGPR.
The market is highly concentrated, suggesting high barriers to entry or limited investment in this target.
ASGPR Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets ASGPR, using sirna modality.
Exploring alternative modalities like antibodies or small molecules represents a whitespace opportunity.
ASGPR Clinical Trials 1 trial
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on ASGPR. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
ASGPR Drug Approval Timeline (2023 - 2023)
The first and most recent drug approval for ASGPR was RIVFLOZA in 2023.
The recent approval suggests renewed interest, but further approvals are needed to confirm sustained viability.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 1 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on ASGPR. A trial counts if an approved drug acting on ASGPR is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.